What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update

Current Opinion in Psychiatry

Volumn 19, Issue 2, 2006, Pages 135-139

  Abbott, Christopher ^a   Bustillo, Juan ^a,b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

First episode; Glutamate; Glutamine; NAA; Schizophrenia; Spectroscopy

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; GLUTAMINE; HALOPERIDOL DECANOATE; N ACETYLASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; ASPARTIC ACID; BIOLOGICAL MARKER; CHOLINE; CREATINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; N METHYLASPARTIC ACID; N-ACETYLASPARTATE; PROTON;

BRAIN METABOLISM; CEREBELLUM; CINGULATE GYRUS; COGNITIVE DEFECT; EXCITOTOXICITY; HUMAN; LOW DRUG DOSE; MENTAL PATIENT; METABOLIC DISORDER; METABOLITE; METHODOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PARIETAL LOBE; PREFRONTAL CORTEX; PROTEIN DEFECT; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SCHIZOPHRENIA; TEMPORAL LOBE; THALAMUS; TIME; BRAIN; CROSSOVER PROCEDURE; METABOLISM; NERVE CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ASPARTIC ACID; BIOLOGICAL MARKERS; BRAIN; CHOLINE; CREATINE; CROSS-OVER STUDIES; GLUTAMIC ACID; GLUTAMINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; N-METHYLASPARTATE; NEURONS; PROTONS; SCHIZOPHRENIA; TEMPORAL LOBE;

EID: 33646825641     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yco.0000214337.29378.cd     Document Type: Review

References (34)

1. Adalsteinsson E, Sullivan EV, Kleinhans N, et al. Longitudinal decline of the neuronal marker N-acetylaspartate in Alzheimer's disease. Lancet 2000; 355:1696-1697.
2. Jung RE, Yeo RA, Chiulli SJ, et al. Biochemical markers of cognition: a proton MR spectroscopy study of normal human brain. Neuroreport 1999; 10:3327-3331.
3. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999; 33:523-533.
4. 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychology 2005; 30:1949-1962. This study is the first meta-analysis completed in the literature for proton spectroscopy and schizophrenia; this meta-analysis examines the results of NAA in various brain regions and compares NAA in first-episode and chronic patients. There is compelling evidence for NAA reduction in schizophrenia. Publication bias cannot be completely excluded.
5. Molina V, Sanchez J, Reig S, et al. N-Acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration. Schizophr Res 2005; 73:209-219. While other studies have failed to show a relationship between NAA and disease duration, this study did find a significant inverse relationship in the left hemisphere. The relatively shorter disease duration in this sample may have permitted identification of the relationship between length of illness and NAA.
6. Ohrmann P, Siegmund A, Suslow T, et al. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res 2005; 73:153-157. This is the first study to show reduced Glx and NAA in chronic schizophrenia patients but normal levels of both early in the illness, and it also provides evidence of disease progression. Long-term longitudinal studies are however necessary.
7. Brooks WM, Hodde-Vargas J, Vargas LA, et al. Frontal lobe of children with schizophrenia spectrum disorders: a proton magnetic resonance spectroscopy study. Biol Psychiatry 1993; 43:263-269.
8. Bertolino A, Kumra S, Callicot JH, et al. Common pattern of cortical pathology of childhood-onset and adult-onset schizophrenia as identified by proton magnetic spectroscopic imaging. Am J Psychiatry 1998; 155:1376-1383.
9. Cecil KM, Lenkinski RE, Gur RE, et al. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naïve patients with schizophrenia. Neuropsychopharmacology 1999; 20:131-140.
10. Bertolino A, Sciota D, Brudaglio F, et al. Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. Am J Psychiatry 2003; 160:483-489.
11. Ho BC, Andreason NC, Nopoulos P, et al. Progressive structural brain abnormalities and their relationship to clinical outcomes. Arch Gen Psychiatry 2003; 60:585-594.
12. Lieberman J, Tollefson GD, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005; 62:361-370.
13. Jakary A, Vonogradov S, Feiwell R, et al. N-Acetylaspartate reductions in the mediodorsal and anterior thalamus in men with schizophrenia verified by tissue volume correction proton MRSI. Schizophr Res 2005; 76:173-185. This is the first study to use spectroscopic imaging focused on the thalamus bilaterally with careful tissue segmentation, which permitted partial volume correction.
14. Ende G, Hubrich P, Walter S, et al. Further evidence for altered cerebellar neuronal integrity in schizophrenia. Am J Psychiatry 2005; 162:790-792. This is the first study that utilized spectroscopic imaging and tissue segmentation in the cerebellum.
15. Miyaoka T, Yasukawa R, Mizuno S, et al. Proton magnetic resonance spectroscopy (1H-MRS) of hippocampus, basal ganglia, and vermis of cerebellum in schizophrenia associated with idiopathic unconjungated hyperbilirubinemia (Gilbert's syndrome). J Psychiatr Res 2005; 39:29-34.
16. Shimizu E, Hashimoto K, Ochi S, et al. Posterior cingulate gyrus metabolic changes in chronic schizophrenia with generalized cognitive deficits. J Psychiatr Res 2005 [Epub ahead of print].
17. Farber NB, Kim SH, Dikranian K, et al. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 2002; 7:32-43.
18. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway for NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1992; 17:2921-2927.
19. Rowland LM. Subanesthetic ketamine: how it alters physiology and behavior in humans. Aviat Space Environ Med 2005; 76 (7 Suppl):C52-C58.
20. Rowland LM, Bustillo JR, Mullins PG, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 2005; 162:394-396. In this study, acute antagonism of NMDA receptors resulted in increased Gln in the anterior cingulate. These results were the first to document in humans that NMDA receptor blockade leads to a paradoxical increase in glutamatergic metabolism as documented in animals. An important missing piece supporting the NMDA receptor hypofunction model of schizophrenia is provided in this paper.
21. Hashimoto K, Engberg G, Shimizu E, et al. Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naïve schizophrenic patients. BMC Psychiatry 2005; 5:6.
22. Theberge J, Bartha R, Drost D, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 2002; 159:1944-1946.
23. Theberge J, Al-Semaan Y, Menon P, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 2003; 160:2231-2233.
24. Tibbo P, Hanstock C, Valiakalayil A, et al. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry 2004; 161:1116-1118. This study reports that no change in NAA with increased Glu and Gln in high-risk group supports glutamatergic dysfunction early in the disease. Results may have been more robust if Glu and Gln could have been measured separately (Gln being more representative of the neurotransmitter Glu).
25. Tebartz van Elst L, Valerius G, Buchert M, et al. Increased prefrontal and hippocampal glutamate and concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry (in press).
26. Bustillo J, Chen H, Griffith G, et al. 4 T proton echo planar spectroscopic imaging (PEPSI) at very short TE. International Society Magnetic Resonance in Medicine, Spectroscopy in Neuropsychiatric Disease Workshop; 2005; Bampf, Canada.
27. Reynolds LM, Cochran SM, Morris BJ, et al. Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartylglutamate in rat brain. Schizophr Res 2005; 73:147-152. According to this study, unlike exposure to antipsychotic medications, 'chronic' NMDAR blockade is a plausible model of the NAA reductions found in schizophrenia. This model has the further advantage of using low dosage of PCP, unlikely to cause widespread neuronal loss. In schizophrenia, the post-mortem literature does not support widespread neuronal loss.
28. Bustillo J, Perrone-Bizzozero N, Paz R, et al. Hypometabolic medial-frontal effects of chronic intermittent PCP exposure in rats assessed with high resolution magic angle spin 11.7 T proton magnetic resonance spectroscopy. Kona, Hawaii: American College of Neuropsychopharmacology; 2005.
29. Harte MK, Bachus SB, Reynolds GP. Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol. Schizophr Res 2005; 75:303-308. This is the first study to document increased NAA in the striatum of rats chronically treated with antipsychotic medication. It suggests that the increased striatal volumes with typical antipsychotics in humans are likely due to an increase in the density of neuronal processes. The absence of changes in NAA in cortical regions in antipsychotic-treated rats suggests that the NAA reductions in patients are not secondary to medication effects.
30. Bustillo J, Barrow R, Paz R, et al. Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology 2005 [Epub ahead of print].
31. Chakos MH, Shirakawa O, Lieberman J, et al. Striatal enlargement in rats chronically treated with neuroleptic. Biol Psychiatry 1998; 44:675-684.
32. Lindquist DM, Hawk RM, Karson CN, et al. Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo. Magn Reson Med 2000; 43:355-358.
33. Bustillo J, Wolff C, Myers-y-Gutierrez A, et al. Treatment of rats with antipsychotic drugs: lack of an effect on N-acetyl-aspartate levels. Schizophr Res 2004; 66:31-39.
34. Dager S, Friedman S, Parow A, et al. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 2004; 61:450-458.